Fig. 1.
Recognition of PD-L1 using anti-PD-L1 mAbs. (A) CHO/PD-L1 cells were treated with L1Mab-13 and 13-mG2a-f (1 μg/mL), followed by secondary antibodies. (B) CHO-K1 cells were treated with L1Mab-13 and 13-mG2a-f (1 μg/mL), followed by secondary antibodies. (C) SAS cells were treated with L1Mab-13 and 13-mG2a-f (1 μg/mL), followed by secondary antibodies. (D) HSC-2 cells were treated with L1Mab-13 and 13-mG2a-f (1 μg/mL), followed by secondary antibodies. The black line represents the negative control.